HRP20201862T1 - Anti-sklerostin protutijelo, antigen vezujući fragment i njegova medicinska uporaba - Google Patents
Anti-sklerostin protutijelo, antigen vezujući fragment i njegova medicinska uporaba Download PDFInfo
- Publication number
- HRP20201862T1 HRP20201862T1 HRP20201862TT HRP20201862T HRP20201862T1 HR P20201862 T1 HRP20201862 T1 HR P20201862T1 HR P20201862T T HRP20201862T T HR P20201862TT HR P20201862 T HRP20201862 T HR P20201862T HR P20201862 T1 HRP20201862 T1 HR P20201862T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- specifically binds
- host cell
- bone
- human sclerostin
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 102000058171 human SOST Human genes 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000019307 Sclerostin Human genes 0.000 claims 1
- 108050006698 Sclerostin Proteins 0.000 claims 1
- 230000037118 bone strength Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Antijelo koje se specifično veže na humani sklerostin, sadrži teški lanac SEK ID BR: 26 i laki lanac SEK ID BR: 29.
2. DNA molekula, koji kodira antitijelo koje se specifično veže na humani sklerostin sukladno patentnom zahtjevu 1.
3. Ekspresijski vektor koji sadrži DNA molekul sukladno patentnom zahtjevu 2.
4. Stanica domaćin, koja se transformirana s ekspresijskim vektorom sukladno patentnom zahtjevu 3.
5. Stanica domaćin sukladno patentnom zahtjevu 4, pri čemu je stanica domaćin stanica sisavca.
6. Stanica domaćin sukladno patentnom zahtjevu 5, pri čemu je CHO stanica.
7. Farmaceutski pripravak, koja sadrži antitijelo sukladno patentnom zahtjevu 1, i jedan ili više farmaceutski prihvatljivog ekscipijensa, otapalo ili nosač.
8. Antitijelo koje se specifično veže na humani sklerostin sukladno patentnom zahtjevu 1 ili farmaceutski pripravak sukladno patentnom zahtjevu 7, za uporabu kao lijek, barem jednim povećanjem koštane mase, mineralne gustoće kostiju, sadržaja minerala sadržaja kostiju ili čvrstoće kostiju.
9. Antitijelo koje se specifično veže na humani sklerostin sukladno patentnom zahtjevu 1 ili farmaceutski pripravak sukladno patentnom zahtjevu 7, za uporabu za liječenje sklerostinom uzrokovane bolesti ili poremećaja kostiju odabrano od osteoporoze, osteopenijskog osteoartritisa, reumatoidnog artritisa, paradontalne bolesti i multiplog mijeloma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510112924 | 2015-03-13 | ||
EP16764142.2A EP3269735B1 (en) | 2015-03-13 | 2016-02-16 | Anti-sclerostin antibody, antigen binding fragment and medical use thereof |
PCT/CN2016/073857 WO2016145961A1 (zh) | 2015-03-13 | 2016-02-16 | 抗硬骨素抗体、其抗原结合片段及其医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201862T1 true HRP20201862T1 (hr) | 2021-01-22 |
Family
ID=56919707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201862TT HRP20201862T1 (hr) | 2015-03-13 | 2020-11-23 | Anti-sklerostin protutijelo, antigen vezujući fragment i njegova medicinska uporaba |
Country Status (20)
Country | Link |
---|---|
US (1) | US10449250B2 (hr) |
EP (2) | EP3782641A1 (hr) |
JP (1) | JP6755513B2 (hr) |
KR (1) | KR102584953B1 (hr) |
CN (2) | CN111196849B (hr) |
AU (1) | AU2016232897B2 (hr) |
BR (1) | BR112017019075A2 (hr) |
CA (1) | CA2978976C (hr) |
DK (1) | DK3269735T3 (hr) |
ES (1) | ES2835923T3 (hr) |
HR (1) | HRP20201862T1 (hr) |
HU (1) | HUE052528T2 (hr) |
LT (1) | LT3269735T (hr) |
MX (1) | MX2017011480A (hr) |
PT (1) | PT3269735T (hr) |
RS (1) | RS61158B1 (hr) |
RU (1) | RU2716101C2 (hr) |
SI (1) | SI3269735T1 (hr) |
TW (2) | TWI730954B (hr) |
WO (1) | WO2016145961A1 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201909913A (zh) * | 2017-07-27 | 2019-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種sost抗體醫藥組成物及其用途 |
CN108101984B (zh) * | 2017-12-18 | 2019-10-15 | 中国人民解放军总医院 | 骨硬化蛋白单链抗体的制备方法和用途 |
US20210198672A1 (en) * | 2018-02-12 | 2021-07-01 | Aptacure Therapeutics Limited | Aptamer for sclerostin and use thereof |
CN113913463B (zh) * | 2021-09-19 | 2023-08-18 | 郭保生 | 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用 |
TW202330032A (zh) * | 2021-11-30 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種抗sost抗體醫藥組成物及其用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0411552A (pt) * | 2003-06-16 | 2006-08-01 | Celltech R & D Inc | anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
EP2094731A2 (en) | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
MY165625A (en) * | 2006-12-26 | 2018-04-18 | Ct Inmunologia Molecular | Pharmaceutical composition comprising an anti- cd6 monoclonal antibody useful for the diagnosis and treatment of rheumatoid arthritis |
SI2131860T1 (sl) * | 2007-03-20 | 2014-02-28 | Eli Lilly And Company | Protitelesa proti sklerostinu |
AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
JP2011506483A (ja) * | 2007-12-14 | 2011-03-03 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体を用いた骨折の治療方法 |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
SG11201401791WA (en) | 2011-10-24 | 2014-08-28 | Abbvie Inc | Immunobinders directed against sclerostin |
SG10201509629QA (en) * | 2011-12-28 | 2015-12-30 | Amgen Inc | Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies |
CN104619342A (zh) | 2012-07-05 | 2015-05-13 | Ucb医药有限公司 | 骨疾病的治疗 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
-
2016
- 2016-02-16 KR KR1020177027816A patent/KR102584953B1/ko active IP Right Grant
- 2016-02-16 LT LTEP16764142.2T patent/LT3269735T/lt unknown
- 2016-02-16 WO PCT/CN2016/073857 patent/WO2016145961A1/zh active Application Filing
- 2016-02-16 RU RU2017132924A patent/RU2716101C2/ru active
- 2016-02-16 MX MX2017011480A patent/MX2017011480A/es unknown
- 2016-02-16 SI SI201630983T patent/SI3269735T1/sl unknown
- 2016-02-16 EP EP20197476.3A patent/EP3782641A1/en active Pending
- 2016-02-16 ES ES16764142T patent/ES2835923T3/es active Active
- 2016-02-16 CN CN201910168894.8A patent/CN111196849B/zh active Active
- 2016-02-16 PT PT167641422T patent/PT3269735T/pt unknown
- 2016-02-16 HU HUE16764142A patent/HUE052528T2/hu unknown
- 2016-02-16 EP EP16764142.2A patent/EP3269735B1/en active Active
- 2016-02-16 CN CN201680001851.5A patent/CN106661104B/zh active Active
- 2016-02-16 DK DK16764142.2T patent/DK3269735T3/da active
- 2016-02-16 AU AU2016232897A patent/AU2016232897B2/en active Active
- 2016-02-16 RS RS20201482A patent/RS61158B1/sr unknown
- 2016-02-16 CA CA2978976A patent/CA2978976C/en active Active
- 2016-02-16 JP JP2017546934A patent/JP6755513B2/ja active Active
- 2016-02-16 BR BR112017019075-3A patent/BR112017019075A2/pt active Search and Examination
- 2016-02-16 US US15/556,488 patent/US10449250B2/en active Active
- 2016-03-02 TW TW105106269A patent/TWI730954B/zh active
- 2016-03-02 TW TW110117739A patent/TWI790617B/zh active
-
2020
- 2020-11-23 HR HRP20201862TT patent/HRP20201862T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201862T1 (hr) | Anti-sklerostin protutijelo, antigen vezujući fragment i njegova medicinska uporaba | |
EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
HRP20190762T1 (hr) | Protutijela koja se vežu prvenstveno na izvanstaničnu domenu 4 ljudskog csf1r i njihova uporaba | |
HRP20201852T1 (hr) | Optimizacija antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
PE20200148A1 (es) | Anticuerpos anti-trem2 y metodos para utilizarlos | |
PE20180046A1 (es) | Anticuerpos terapeuticos y sus usos | |
CL2012003283A1 (es) | Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8. | |
PE20141045A1 (es) | Proteinas de union a bcma (cd269/tnfrsf17) | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
WO2015108998A8 (en) | Cartilage targeting agents and their use | |
HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
BR112012030664A2 (pt) | proteína de ligação de antígeno humanizada, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para a produção de uma proteína de ligação de antígeno, para tratar um indivíduo afligido com uma doença e para aumentar a massa muscular, aumentar a força muscular, e/ou melhorar a função muscular em um paciente, e, composição farmacêutica. | |
AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
PE20150960A1 (es) | Inmunoglobulinas heterodimericas | |
CL2013003552A1 (es) | Anticuerpo aislado que se une a la proteina 3 humana de tipo angiopoyetina (hangptl3); molécula de ácido nucleico; vector de expresión, célula hospedera; método de producción de un anticuerpo. | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
JP2016502515A5 (hr) | ||
RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения |